Need Help?
Contact Us

Caution: Eluvia is an investigational device. Limited by US law to investigational use only. Not available for sale.

"The drug-delivery platform for Eluvia is unique among drug-eluting stents that have come before it for the SFA…I think the Eluvia represents a potential advantage even over those earlier technologies because of its tuned paclitaxel elution profile."

William Gray, MD
Prin. Investigator, IMPERIAL Trial
Lankenau Heart Institute/Main Line Health | Wynnewood, PA

Chart showing the MAJESTIC 2-year primary patency rate for the Eluvia Drug-Eluting Vascular Stent System is 83.5%.

MAJESTIC 1- and 2-Year Primary Patency1


Clinically Studied Therapies


Find out how Boston Scientific’s drug-eluting technologies continue to deliver unprecedented clinical outcomes in patients with peripheral artery disease (PAD).

Close up of the Eluvia Drug-Eluting Vascular Stent System

Eluvia Drug-Eluting Vascular Stent System

The Eluvia Drug-Eluting Stent showed unprecedented clinical outcomes—with a 83.5% primary patency at 2 years, the highest reported in comparable SFA clinical trials.

Chart comparing paclitaxel release over time for the Eluvia Drug-Eluting Stent, drug-coated balloons and traditional drug-coated stents.

Drug Tissue Concentrations Over Time 2


Investing in Drug-Eluting Technology


Find out how we’re leveraging nearly 20 years of design and development experience to advance the science of drug-eluting technologies and improve patient lives.

 

Dr. Erwin Blessing discusses data showing that drug-eluting stent technology outperforms bare metal stents.

"We have clear data that the drug-eluting stent technology outperforms a bare metal stent."

Professor Erwin Blessing, MD
SRH Hospital | Karlsbad, Germany

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top